Cerus Corporation (CERS)
Largest Insider Buys in Sector
CERS Stock Price History Chart
CERS Stock Performance
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood …
Insider Activity of Cerus Corporation
Over the last 12 months, insiders at Cerus Corporation have bought $67,242 and sold $1.03M worth of Cerus Corporation stock.
On average, over the past 5 years, insiders at Cerus Corporation have bought $215,060 and sold $3.59M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BJERKHOLT ERIC (director) — $48,600. Witney Frank (director) — $37,800. Swisher Daniel N JR (director) — $14,066.
The last purchase of 2,500 shares for transaction amount of $4,975 was made by Shan Hua (director) on 2024‑05‑13.
List of Insider Buy and Sell Transactions, Cerus Corporation
| 2024-09-04 | Sale | Chief Financial Officer | 54,272 0.0299% | $2.15 | $116,826 | -16.35% | ||
| 2024-09-03 | Sale | Chief Financial Officer | 28,385 0.0153% | $2.18 | $61,919 | -18.72% | ||
| 2024-08-15 | Sale | Chief Legal Officer | 16,667 0.0092% | $2.06 | $34,417 | 0.00% | ||
| 2024-08-02 | Sale | Chief Medical Officer | 21,605 0.0125% | $2.50 | $54,013 | -17.87% | ||
| 2024-05-13 | director | 2,500 0.0013% | $1.99 | $4,975 | -6.75% | |||
| 2024-05-10 | director | 2,000 0.0011% | $1.79 | $3,578 | +8.09% | |||
| 2024-05-09 | director | 20,000 0.0107% | $1.89 | $37,800 | -2.86% | |||
| 2024-05-09 | director | 2,500 0.0013% | $1.88 | $4,689 | -2.86% | |||
| 2024-03-14 | Sale | President and CEO | 63,611 0.0349% | $2.02 | $128,195 | -8.04% | ||
| 2024-03-14 | Sale | Chief Scientific Officer | 14,360 0.0077% | $1.97 | $28,352 | -8.04% | ||
| 2024-03-14 | Sale | Chief Operating Officer | 26,794 0.0144% | $1.97 | $52,902 | -8.04% | ||
| 2024-03-14 | Sale | Chief Financial Officer | 21,497 0.0116% | $1.97 | $42,444 | -8.04% | ||
| 2024-03-14 | Sale | Chief Legal Officer | 17,824 0.0096% | $1.97 | $35,192 | -8.04% | ||
| 2024-03-14 | Sale | Chief Medical Officer | 17,738 0.0095% | $1.97 | $35,022 | -8.04% | ||
| 2024-03-13 | Sale | President and CEO | 62,315 0.0349% | $2.06 | $128,182 | -9.16% | ||
| 2024-03-13 | Sale | Chief Scientific Officer | 14,067 0.0079% | $2.06 | $28,936 | -9.16% | ||
| 2024-03-13 | Sale | Chief Operating Officer | 26,247 0.0147% | $2.06 | $53,990 | -9.16% | ||
| 2024-03-13 | Sale | Chief Financial Officer | 21,058 0.0116% | $2.02 | $42,438 | -9.16% | ||
| 2024-03-13 | Sale | Chief Legal Officer | 17,460 0.0098% | $2.06 | $35,915 | -9.16% | ||
| 2024-03-13 | Sale | SVP Reg. & Quality | 20,619 0.0113% | $2.02 | $41,553 | -9.16% |
Insider Historical Profitability
| Greenman William Mariner | President and CEO | 3181281 1.713% | $1.79 | 5 | 12 | +31.07% |
| CORASH LAURENCE M | Chief Scientific Officer | 2339740 1.2599% | $1.79 | 37 | 8 | +15.14% |
| Witney Frank | director | 180059 0.097% | $1.79 | 2 | 0 | +47.63% |
| BJERKHOLT ERIC | director | 142133 0.0765% | $1.79 | 4 | 0 | +22.01% |
| NACHTSHEIM JAMI K | director | 108362 0.0583% | $1.79 | 2 | 0 | +47.63% |
Institutional Investor Ownership
| ARK Investment Management LLC | $40.72M | 11.65 | 21.55M | +3.02% | +$1.19M | 0.14 | |
| Baker Bros Advisors LP | $36.81M | 10.54 | 19.48M | 0% | +$0 | 0.26 | |
| BlackRock | $25.77M | 7.38 | 13.64M | -0.67% | -$172,825.38 | <0.01 | |
| The Vanguard Group | $18.87M | 5.4 | 9.98M | +1.15% | +$214,121.88 | <0.0001 | |
| PRIMECAP Management Co | $16.22M | 4.64 | 8.58M | -0.34% | -$54,810.00 | 0.01 |